The largest database of trusted experimental protocols

18 protocols using moxifloxacin

1

Empyema Treatment with Moxifloxacin and Doripenem

Check if the same lab product or an alternative is used in the 5 most similar protocols
After an empyema was corroborated, Moxifloxacin (25 mg/kg-1) (Avelox, Bayer, Istanbul, Turkey) and Doripenem (20 mg/kg-1) (Janssen-Cilag, NJ, USA) were administered intraperitoneally over three minutes.
+ Open protocol
+ Expand
2

Melanocyte Culture Reagents and Supplements

Check if the same lab product or an alternative is used in the 5 most similar protocols
Norfloxacin, phosphated-buffered saline (PBS), 3,4-dihydroxy-l-phenylalanine (L-DOPA) and amphotericin B were purchased from Sigma-Aldrich Inc.(USA). moxifloxacin hydrochloride (AveloxTM solution for i.v. use containing 400 mg of moxifloxacin in 0.8 % saline) was obtained from Bayer Healthcare Pharmaceuticals Inc. (Germany). Neomycin sulfate was obtained from Amara (Poland). Penicillin was acquired from Polfa Tarchomin (Poland). Growth medium M-254 and human melanocyte growth supplement-2 (HMGS-2) were obtained from Cascade Biologics (UK). Trypsin/EDTA was obtained from Cytogen (Poland). Cell Proliferation Reagent WST-1 was purchased from Roche GmbH (Germany). The remaining chemicals were produced by POCH S.A. (Poland).
+ Open protocol
+ Expand
3

Randomized Trial of Tetrodotoxin Doses

Check if the same lab product or an alternative is used in the 5 most similar protocols
Study schematic is shown in Figure 5. A total of 25 eligible subjects were randomized in a double-blind manner to either a treatment or control arm. Subjects randomized to the treatment arm received single subcutaneous (s.c.) doses of 15 µg, 30 µg, and 45 µg TTX in sterile water (Halneuron® manufactured by K.A.B.S. Laboratories Inc, Quebec, Canada for WEX Pharmaceuticals Inc.) over 3 periods with a 7-day washout interval between each period. Subjects assigned to the control arm using Celerion’s computerized randomization scheme were further randomized to one of two sequences (placebo-Moxifloxacin-placebo or Moxifloxacin-placebo-Moxifloxacin) and received placebo and Moxifloxacin in a crossover fashion over 3 periods. All subjects were admitted at least 12 h before dosing on day 1 of each period and remained domiciled for approximately 24 h until all assessments were completed on day 2. Moxifloxacin (400 mg, Bayer Pharmaceuticals, West Haven, CT, USA) was used as a positive control to demonstrate assay sensitivity. In crossover designed studies with healthy subjects, 400 mg Moxifloxacin has been shown to prolong heart rate-corrected QT interval by 10–15 ms compared to placebo [42 (link),58 (link),59 (link)].
+ Open protocol
+ Expand
4

Antibiotics Preparation for Cell Culture

Check if the same lab product or an alternative is used in the 5 most similar protocols
Antibiotic powders of daptomycin (Merck & Co. Inc., Kenilworth, NJ) and quinupristin/dalfopristin (AG Scientific, San Diego, CA) were dissolved in sterile water for injection and stored as stocks at −20 °C. Sterile liquid formulations of clindamycin (Pfizer, New York, NY), moxifloxacin (Bayer AG, Leverkusen, Germany), gentamicin (GPO, Bangkok, Thailand), and amikacin (Siam Bheasach, Bangkok, Thailand) were stored at 4 °C. Final antibiotic solutions were freshly prepared before use by diluting stock solutions with cell culture medium.
+ Open protocol
+ Expand
5

Synthesis of Antitubercular Compounds

Check if the same lab product or an alternative is used in the 5 most similar protocols
1599 and 1810 were synthesized as described (Figure S1).3 (link) Isoniazid, rifampicin, pyrazinamide, ethambutol, levofloxacin, kanamycin, amikacin, ethionamide, ofloxacin, cycloserine, rifapentine and clofazimine were purchased from Sigma-Aldrich. Linezolid was purchased from 21CEC. Moxifloxacin was obtained from Bayer. PA-824 (Pretomanid) was obtained from the Global Alliance for TB Drug Development. Bedaquiline (Sirturo) was provided by Johnson and Johnson. SQ109 was synthesized as described.9 (link)
+ Open protocol
+ Expand
6

Antibiotic Stock Solutions and Media Preparation

Check if the same lab product or an alternative is used in the 5 most similar protocols
Stock solutions were prepared for ofloxacin (Sigma–Aldrich), levofloxacin (Sigma–Aldrich), moxifloxacin (Bayer or Molekula) and gatifloxacin (Lupin, India or Sigma–Aldrich) at 10 000 mg/L in 0.1 N sterile NaOH and stored in aliquots at below −18°C for 1 year maximum. Leftover thawed aliquots were not refrozen.
Middlebrook 7H9 broth medium was prepared by adding distilled water, 10% Middlebrook OADC [Becton Dickinson (BD)], 0.5% glycerol (Sigma–Aldrich) and 0.1% casitone (BD) to Middlebrook 7H9 powder (BD) and stored at 2–8°C for 3 months maximum.
+ Open protocol
+ Expand
7

Antibiotic Susceptibility of Toxigenic C. difficile

Check if the same lab product or an alternative is used in the 5 most similar protocols
The susceptibilities of the 284 toxigenic C. difficile clinical isolates to 15 antimicrobial agents were determined by the agar dilution method described by the Clinical and Laboratory Standards Institute (CLSI)24 . The antimicrobial agents tested include cefotaxime, cefoperazone, ceftazidime (GlaxoSmithKline), ciprofloxacin, clindamycin, erythromycin, fusidic acid, levofloxacin, metronidazole (B. Braun Medical Industries), meropenem (Astra Zeneca), moxifloxacin (Bayer), piperacillin-tazobactam, rifampicin, tetracycline and vancomycin, all reagents were purchased from Sigma unless otherwise stated. C. difficile ATCC 700057 and Bacteroides fragilis ATCC 25285 were used as control strains for each run of agar dilution testing. The minimal inhibitory concentration (MIC) was defined as the lowest concentration of the drug that inhibits bacterial growth. The breakpoints for metronidazole, clindamycin, tetracycline, moxifloxacin, meropenem, piperacillin-tazobactam, cefotaxime and cefoperazone were determined with MIC criteria described by CLSI guidelines24 . For vancomycin and fusidic acid, breakpoints recommended by the European Committee on Antimicrobial Susceptibility Testing (EUCAST) were used25 . For erythromycin, ciprofloxacin, levofloxacin, and rifampicin, we adapted the breakpoints from Huang et al.26 (link). No breakpoint for ceftazidime was available at the time of this study.
+ Open protocol
+ Expand
8

Antimicrobial Susceptibility Testing for Mycoplasmas

Check if the same lab product or an alternative is used in the 5 most similar protocols
The antimicrobials for susceptibility testing were azithromycin (Novatec, Cuba), erythromycin (Sigma, USA), ciprofloxacin (Sigma, USA), ofloxacin (Sigma, USA), levofloxacin (Novatec, Cuba), moxifloxacin (Bayer, Italy), tetracycline (Sigma, USA) and doxycycline (Bayer, Italy). All compounds were diluted and conserved according to the specifications in the CLSI-Guideline M43-A: “Methods for Antimicrobial Susceptibility Testing for Human Mycoplasmas” [15 ].
+ Open protocol
+ Expand
9

Antibiotic Susceptibility Screening

Check if the same lab product or an alternative is used in the 5 most similar protocols
The MICs of 11 antibiotics, including penicillin G, cefotaxime, chloramphenicol, tetracycline, erythromycin, lincomycin, ciprofloxacin (Sigma, St. Louis, MO, USA), levofloxacin (Daiichi Sankyo, Tokyo, Japan), gatifloxacin (Bristol-Myers Squibb, Moreton, UK), moxifloxacin (Bayer Healthcare Pharmaceuticals, Berlin, Germany), and linezolid (Pfizer, NJ, USA), were determined using the microbroth dilution method, according to the Clinical and Laboratory Standards Institute (CLSI).
+ Open protocol
+ Expand
10

Time-Kill Kinetics of Fluoroquinolones

Check if the same lab product or an alternative is used in the 5 most similar protocols
Antibiotics were supplied by their respective manufacturers as pure titrated powders (ciprofloxacin and moxifloxacin by Bayer Healthcare SAS, levofloxacin by Sanofi-Aventis, France). Five strains of each species were selected for time-kill studies, based on their different susceptibility patterns to the antibiotics (Table 2). For each strain, time kill studies were performed for the three molecules at concentrations equal to the theoretical plasma peak (ciprofloxacin = 4 μg/mL; levofloxacin = 10 μg/mL; moxifloxacin = 3 μg/mL), then at concentrations equal to one fold and two fold the MIC of the antibiotic used. Bacteria were initially cultured for 24 h at 37°C on Mueller-Hinton agar. These cultures were then considered as being on stationary growth-phase and used to prepare exponential growth phase at standard inoculum (106 CFU/mL) in Mueller-Hinton broth (MHB, bioMérieux, France). The inoculum of 106 CFU/ml was obtained by standardizing optical density at 550 nm to 0.125 followed by a 1:100 dilution. Final suspensions of bacteria were supplemented with ciprofloxacin, levofloxacin or moxifloxacin at different concentrations and cultured for 24 h at 37°C. Culture aliquots of 100 ml were removed at 2, 4, 6 and 24 h and plated on agar for colony counts.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!